Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Authors
Keywords
-
Journal
CELL RESEARCH
Volume 29, Issue 8, Pages 609-627
Publisher
Springer Science and Business Media LLC
Online
2019-07-02
DOI
10.1038/s41422-019-0184-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2019) Miguel F. Sanmamed et al. CELL
- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
- (2018) Xuexiang Du et al. CELL RESEARCH
- A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
- (2018) Xuexiang Du et al. CELL RESEARCH
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Rheumatic immune-related adverse events from cancer immunotherapy
- (2018) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
- (2018) Hussein A. Tawbi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
- (2018) Rodabe N. Amaria et al. NATURE MEDICINE
- Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
- (2018) Christian U. Blank et al. NATURE MEDICINE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Probe for the measurement of cell surface pH in vivo and ex vivo
- (2016) Michael Anderson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
- (2015) Michal Pyzik et al. JOURNAL OF IMMUNOLOGY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
- (2015) B. Lo et al. SCIENCE
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4
- (2014) H. S. Kuehn et al. SCIENCE
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- (2013) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
- (2013) Yannick Bulliard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
- (2013) Tyler R. Simpson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
- (2013) M. J. Selby et al. Cancer Immunology Research
- Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
- (2010) Tomoyuki Igawa et al. NATURE BIOTECHNOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- CTLA-4 Control over Foxp3+ Regulatory T Cell Function
- (2008) K. Wing et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now